P. Di Lucia

This study shows that nirmatrelvir treatment in SARS-CoV-2 infected mice reduces antibody and T cell responses, leading to weaker memory cell recruitment upon secondary challenge.

This study develops an aerosolized SARS-CoV-2 infection model in K18-hACE2 mice that replicates respiratory symptoms without fatal neuroinvasion, offering a more accurate representation of human COVID-19 pathogenesis.

This study demonstrates that OMV-based SARS-CoV-2 vaccines induce neutralizing antibodies and protect mice from viral challenge.

This paper evaluates a DNA vaccine candidate, COVID-eVax, which induces strong neutralizing antibodies and T cell responses against SARS-CoV-2 in animal models, showing protective effects against viral challenge.